Snackable artificial intelligence, expert AI, and the pharma industry

AdobeWhileit’swidelyacceptedthatthepharmaindustryisinnovativeinR&D,itisalsotruethatitcanbeslowat AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul




fashion

author:focus    Page View:2
Glaxo Smith Kline
Akira Suemori/AP

A few years ago, Vijay Pande, then a professor at Stanford who was using computer science to understand biology, was deciding whether to leave full-time academic work to become a venture capitalist. He turned to Andrew Ng, another Stanford professor who had joined Google Brain and later the Chinese search firm Baidu.

“The things that we dreamed about five or 10 years ago were happening now,” Pande recalled Ng telling him. “The question was, do you want to be a part of it? Or do you want to write another paper?”

advertisement

Pande decided to become a venture capitalist. The result, he told an audience at a STAT event in San Francisco last week, is that, whereas he managed about $1 million to $2 million in research as a top academic, he now works at the fabled Silicon Valley firm Andreessen Horowitz, which invests $100 million a year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In